Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 50,320 shares at $66.70 ($3.4M) on 2024-02-02, disclosed to the SEC on 2024-02-05.
Scheduled sale ($3.4M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.70 | 16,435 | $1.1M | 32.5% |
| 2 | $66.70 | 16,435 | $1.1M | 32.5% |
| 3 | $67.42 | 17,450 | $1.2M | 34.9% |
| Total | $66.95 avg | 50,320 | $3.4M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |